Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes
Diabetes Care · 01.05.2023 · 46 (5) · 998-1004
DOI: 10.2337/dc22-1710 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, online erschienen am 01.03.2023. Verfasst von Tim Heise und 11 weiteren Autor:innen. Beteiligte Einrichtung: 1Profil, Neuss, Germany. Hauptthemen laut MEDLINE: Appetite, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 199-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Eli Lilly and Company.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To evaluate the effects of tirzepatide on body composition, appetite, and energy intake to address the potential mechanisms involved in body weight loss with tirzepatide. RESEARCH DESIGN AND METHODS In a secondary analysis of a randomized, double-blind, parallel-arm study, the effects of tirzepatide 15 mg (N = 45), semaglutide 1 mg (N = 44), and placebo (N = 28) on body weight and composition, appetite, and energy intake were assessed at baseline and week 28. RESULTS Tirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide, resulting in greater fat mass reduction. Tirzepatide and semaglutide significantly reduced appetite versus placebo. Appetite scores and energy intake reductions did not differ between tirzepatide and semaglutide. CONCLUSIONS Differences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes. Further evaluation is needed to assess mechanistic differences related to tirzepatide actions on 24-h energy intake, substrate utilization, and energy expenditure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- 1Profil, Neuss, Germany.
- 2Eli Lilly and Company, Indianapolis, IN.
ORCID-Profile: Tim Heise, J Hans DeVries, Shweta Urva, Edward J Pratt, Melissa K Thomas, Julia Dunn, Axel Haupt, Zvonko Milicevic, Tamer Coskun
Förderung
- Eli Lilly and Company
Zitieren
APA
Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., Milicevic, Z., & Coskun, T. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care, 46(5), 998-1004. https://doi.org/10.2337/dc22-1710
Vancouver
Heise T, DeVries JH, Urva S, Li J, Pratt EJ, Thomas MK, et al. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. Diabetes Care. 2023;46(5):998-1004. doi:10.2337/dc22-1710
BibTeX
@article{Heise2023,
author = {Heise, Tim and DeVries, J Hans and Urva, Shweta and Li, Jing and Pratt, Edward J and Thomas, Melissa K and Mather, Kieren J and Karanikas, Chrisanthi A and Dunn, Julia and Haupt, Axel and Milicevic, Zvonko and Coskun, Tamer},
title = {Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes},
journal = {Diabetes Care},
year = {2023},
volume = {46},
number = {5},
pages = {998--1004},
doi = {10.2337/dc22-1710}
}
EUVIMED